YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

1558

CNE1000023R6

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
12.5 ^HKD	+3.48%		+2.29%	+31.72%

Apr. 09	Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	MT
Apr. 01	Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	MT

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Omits Dividend for the Six Months Ended June 30, 2021

August 27, 2021 at 10:24 am EDT

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced that the Board resolved not to declare the payment of an interim dividend for the six months ended June 30, 2021 (for the six months ended June 30, 2020: RMB 0.1 per share (tax inclusive)).

Latest news about YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	Apr. 09	MT
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	Mar. 31	MT
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023	Mar. 28	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023	Mar. 12	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2023	Mar. 12	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Enter into Drug R&D Pipeline Cooperation Project Framework Agreement	Nov. 29	CI
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts	Nov. 08	MT
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China	23-09-26	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration	23-09-25	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes	23-09-08	CI
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales	23-09-01	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug	23-08-16	MT
National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Yiqibuvir Tablets	23-08-15	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director	23-08-14	CI
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%	23-07-27	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	23-07-26	CI
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone	23-07-06	MT
HEC Chang Jiang Pharma Completes Equity Transfer in Unit	23-06-28	MT
GUO Meilan and ZHANG Yushuai completed the acquisition of 9.9134% stake in Sunshine Lake Pharma Co., Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd..	23-06-26	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
YiChang HEC ChangJiang Pharma to Return to Profitability	23-03-20	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Unaudited Earnings Guidance for the Year Ended 31 December 2022	23-03-17	CI
YiChang HEC ChangJiang Pharmaceutical Shareholders to Vote on Disposal of 10% Stake in Controlling Shareholder	23-03-10	MT

Chart YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Duration

Period

Chart YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

More charts

Company Profile

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.18 CNY

Average target price

12.94 CNY

Spread / Average Target

+15.80%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.	+31.72%	1.36B
NOVO NORDISK A/S	+24.24%	562B
JOHNSON & JOHNSON	-6.43%	358B
MERCK & CO., INC.	+18.96%	322B
ABBVIE INC.	+7.12%	297B
ASTRAZENECA PLC	+13.21%	219B
NOVARTIS AG	+6.03%	199B
ROCHE HOLDING AG	-10.35%	196B
PFIZER, INC.	-10.85%	149B
AMGEN INC.	-6.90%	146B

Other Pharmaceuticals